Vascular endothelial growth factor receptor 2 (VEGFR2), a major factor responsible for tumor angiogenesis, is an attractive target for novel anticancer therapies.[8] The new small molecule VEGFR inhibitor apatinib, a drug that has been independently developed in China as a third-line treatment option for advanced GC, has achieved reliable efficacy results. This evidence concerns the gene KDR and gastric cancer.